Modelling and simulation in clinical drug development

被引:19
作者
Rooney, KF [1 ]
Snoeck, E [1 ]
Watson, PH [1 ]
机构
[1] Pharsight Corp, Argentum Ctr, London W6 9DT, England
关键词
D O I
10.1016/S1359-6446(01)01855-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmaceutical companies are under greater pressure than ever before to improve the R&D process. There is a growing need to increase productivity in R&D, and to use technologies that can both increase and more efficiently facilitate the flow of products through the development pipeline. This article describes how the twin processes of modelling and simulation are being used to improve the efficiency of the clinical drug-development process, and consequently how these methodologies have delivered significant benefits in the drive to save time, money (and additionally assisted in ensuring an 'optimal quality' drug label) in the development of novel therapeutic agents.
引用
收藏
页码:802 / 806
页数:5
相关论文
共 5 条
[1]  
Hale MD, 1996, APPL CLIN TRIALS, V5, P35
[2]   Simulation of clinical trials [J].
Holford, NHG ;
Kimko, HC ;
Monteleone, JPR ;
Peck, CC .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2000, 40 :209-234
[3]  
*PRIC, 1998, PHAR 2005 IND REV R
[4]  
SALE M, 2001, DRUG DISCOV, P47
[5]  
SNOECK E, 1999, GOOD CLIN PRAC, V6, P12